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Abstract: Corticosteroids constitute an ideal treatment for various inflammatory and 
autoimmune disorders due to their anti-inflammatory and immunomodulatory actions. 
  However, corticosteroids have a considerable number of side effects, including hypertension, 
diabetes, lipid disorders, sleep apnea, osteoporosis, myopathy, and disorders of coagulation 
and fibrinolysis, which are components of Cushing’s syndrome (CS). Corticosteroid-induced 
side effects are dependent on the formulation, route, dose, and time of exposure. However, the 
underlying pathogenetic mechanisms have not been clearly defined. A large body of evidence 
supports the role of an imbalance between vasoconstriction and vasodilation with possible links 
to nitric oxide, prostanoids, angiotensin II, arginine vasopressin, endothelins, catecholamines, 
neuropeptide Y, and atrial natriuretic peptide. Increased oxidative stress, renin–angiotensin 
system activation, increased pressor response, metabolic syndrome, and sleep apnea appear to 
be pathogenetically involved as well. The ideal treatment is the withdrawal of corticosteroids, 
which is most often impossible due to the exacerbation of the underlying disease. Alternatively, 
a careful plan, including the proper selection of the formulation, time, and route, should be 
made, and each side effect should be treated properly. The focus of the research should be to 
develop synthetic corticosteroids with anti-inflammatory effects but fewer metabolic effects, 
which so far has been unsuccessful.
Keywords: corticosteroids, hypertension, iatrogenic Cushing’s syndrome
Introduction
It is estimated that up to 0.5% of the US population are on chronic corticosteroid 
therapy for various inflammatory and autoimmune disorders.1,2 Annually, ∼10 million 
new prescriptions for oral corticosteroids are issued in the US. A minority of patients 
use corticosteroids without being aware of this, due to their use in the black market. 
  Corticosteroids have been used, along with hydroquinone and mercury, as ingredients 
in a variety of skin lightening (bleaching) cosmetics and toiletries that are widely used 
in African countries.3 Over-the-counter combination preparations of steroids with other 
drugs such as antifungals may lead to unsupervised and inappropriate use of topical 
corticosteroids.2,4,5 Cases of factitious Cushing’s syndrome (CS) from surreptitious use 
of corticosteroids have been described.6 Corticosteroids as an ingredient of a black 
market drug used by addicts to help them through the narcotic withdrawal stage were 
responsible for an outbreak of CS in Tehran in 2008.7
Corticosteroids have been the medication of choice in various disorders, based 
on their undoubted benefits from their anti-inflammatory and immunomodula-
tory actions. However, they are also complicated by a considerable number of side Integrated Blood Pressure Control 2011:4 submit your manuscript | www.dovepress.com
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effects, including CS. The clinical presentation of CS often 
strikes with the use of high doses of corticosteroids.1,2 
Symptoms include central obesity, plethora, easy bruis-
ing, thin skin, striae, myopathy, depression or psychosis, 
poor wound   healing, increased   incidence of infection, 
glaucoma and other   ocular disease, and hypertension (HT). 
Hirsutism and other   virilizing features are uncommon clini-
cal findings due to nonsignificant increases in androgens. 
Avascular necrosis and spinal epidural lipomatosis constitute 
a complication of corticosteroid-induced CS.1,2
All synthetic derivatives that are used clinically, including 
prednisone, prednisolone, methylprednisolone, dexametha-
sone (DX), betamethasone, and triamcinolone, have the 
potential for adverse effects and CS.2 Which of these agents 
is most likely to cause CS has not been fully clarified due 
to the complex interaction of many factors involved in this 
process.2 It appears that it is dependent on the formulation 
used, pharmacokinetics, affinity for the glucocorticoid 
receptor, biologic potency, duration of action, and different 
levels of sensitivity in individual patients.2 Oral corticosteroid 
therapy has been well correlated with CS, and most physi-
cians are aware of the dangers,   having always to balance the 
cost–effect ratio.2 According to accumulated data, topical, 
aerosol, inhaled, and injectable corticosteroid therapy may 
also have adverse effects, including CS.2,8–12 There have 
been several cases of children who received intralesional 
injections into keloid scars or other wounds (such as burns) 
and developed CS that persisted for a long time (up to 
9 months).13 Cases of CS have also been reported in patients 
under treatment with paraspinal depot injections.14 Additional 
unusual cases include CS induced by serial occipital nerve 
blocks containing triamcinolone.15 Corticosteroid-related 
side effects including CS are common in patients with 
cystic fibrosis or HIV infection, which need combined treat-
ments including budesonide and itraconazole or fluticasone 
propionate and ritonavir.11,12,16,17
Another critical determinant of the corticosteroid-induced 
side effects including CS is the dosage needed to control 
the disease. High doses of corticosteroids even for a short 
time or long-term use of agents with lower potency and 
short half-lives (hydrocortisone and cortisone) have been 
associated with CS. However, the prediction of dosages at 
which CS will develop is a complicated phenomenon that 
depends on a variety of factors.1,2 Thus, the cost–effect ratio 
has to be estimated in each case, and a careful plan should 
be made before starting treatment with corticosteroids. 
This review will discuss the critical determinants and 
underlying pathogenetic mechanisms of CS associated with 
corticosteroids.
Morbidities associated  
with corticosteroid-related CS
Corticosteroid-induced CS and HT
HT is a prominent feature in patients with corticosteroid-
induced CS, occurring in up to 20% of cases, and is dose 
dependent.1,2,18,19 A variety of mechanisms has been proposed 
to explain its pathogenesis.18,19
A large body of evidence supports the theory that 
corticosteroids induce an imbalance between vasoconstriction 
and vasodilation, favoring vasoconstriction, resulting in 
HT.18,19 According to in vitro, in vivo, and also human data, 
increased vasoconstriction is in large part mediated by 
increased endothelin-1 synthesis and secretion.20–22   Increased 
cytosolic calcium levels  downregulate the expression of 
the Na–Ca exchanger and increased erythropoeitin levels 
have also been pathogenetically involved in corticosteroid-
induced vasoconstriction and HT.23,24   Accumulating data 
suggest that increased sympathetic activity, reflected in the 
increased synthesis of   catecholamines and a1β-adrenergic 
receptor expression, is an important underlying pathogenetic 
mechanism as well.18,19 The increased synthesis of cat-
echolamines is due to increased expression and activity of 
various enzymes involved in the catecholamine biosynthesis, 
including tyrosine hydroxylase and phenylethanolamine 
N-methyltransferase. Elevated epinephrine and norepineph-
rine levels in plasma and adrenal medulla and increased 
expression and activity of tyrosine hydroxylase have been 
found in hypertensive rats treated with subcutaneous 
injections of dexamethasone (DX; 1 mg/kg/day for 2 days).25 
Elevated levels of plasma dopamine and epinephrine 
have been found in humans treated with a single dose of 
2 mg DX.26 In both studies, the observed effects were blocked 
by the administration of alpha-methyl-p-tyrosine, an inhibitor 
of tyrosine hydroxylase.25,26 Increased activity of phenyle-
thanolamine N-methyltransferase has been found in both 
intact and adrenalectomized rats treated with subcutaneous 
injections of DX (1 mg/kg/day for 12–14 days).27,28 In 
  addition, in vitro, in vivo, and human studies suggest 
that   corticosteroids alter the availability of α1-adrenergic 
receptors in vascular smooth muscles, leading to increased 
vascular reactivity, pressor responsiveness, and HT.29–31
Increased corticosteroid-induced vasoconstriction and 
thus HT are also mediated through enhanced synthesis and 
action of vasoactive substances and their receptors, including Integrated Blood Pressure Control 2011:4 submit your manuscript | www.dovepress.com
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neuropeptide Y (NPY), arginine vasopressin (AVP), and 
atrial natriuretic peptide (ANP).19,20 Increased corticosteroid-
induced NPY gene expression and tissue content in 
neuroendocrine tissue and cell lines have been associated 
with vasoconstriction.32 Coadministration of AVP and DX 
(1.8 mg/kg/week for 2 weeks) to normotensive rats resulted 
in dose-dependent increases in mean arterial pressure, which 
can be reversed by the administration of d(CH2)5Tyr(Me)
AVP, an AVP-V1 receptor antagonist, suggesting the role 
of the V1aAVP receptor in DX-induced HT.31,33,34 Increased 
expression of atrial, ventricular, pulmonary ANP genes 
and plasma ANP levels have been found in both intact and 
adrenalectomized rats treated with DX (1 and 4 mg/kg/day 
for 2 days).31,35 Higher ANP levels have been observed in 
atrial slices and extracts obtained from rats treated with DX 
(intraperitoneally, 0.1 mg/kg/day for 4 days).36,37
Another interesting issue is the role of renin–angiotensin 
system activation in the development of corticosteroid-
induced HT.18,19 Corticosteroids act directly at the liver 
site, enhancing the synthesis of the plasma renin   substrate 
(angiotensinogen).31,38 Experimental studies using 
saralasin, an angiotensin antagonist, and SQ14225, an 
angiotensin-converting enzyme, partly prevented HT in rats 
treated with DX (0.17–0.27 mg/kg/day), suggesting the partial 
contribution of angiotensin II in terms of increased synthesis 
or sensitivity in the development of DX-induced HT.38
A large body of evidence supports the theory that apart 
from the increased corticosteroid-induced synthesis and 
secretion of vasoactive substances, an increased sensitivity 
and reactivity of various tissues to their action, reflected 
in increased vascular pressor responsiveness, has also 
been observed.31,39–41 A reduced threshold and increased 
maximal response to norepinephrine has been observed in 
rat mesenteric vasculatures isolated from hypertensive rats 
treated with DX orally (7–9.5 mg/kg/day for 28 days).42,43
AVP, but not norepinephrine or angiotensin II infusion, 
elicited increased pressor response in DX-induced hyper-
tensive rats (257 mg/kg/day for 2 weeks).33 Infusion of 
angiotensin II in humans treated with DX (orally, 3 mg/day) 
resulted in increased forearm vascular resistance.39,44 These 
effects seem to be mediated through changes in the activity 
of sodium/potassium pump45 and function of glucocorticoid46 
and mineralocorticoid47 receptors as well. Administration of 
angiotensin II and AVP in DX-treated experimental animals 
was accompanied by a reduction in the threshold of the inosi-
tol triphosphate production and HT, an effect that was blocked 
by the administration of a specific glucocorticoid receptor 
antagonist RU38486 but not spironolactone or RU28318, 
type I mineralocorticoid receptor antagonists.46,48 DX-induced 
stimulation of vascular angiotensin II type 1 receptor has also 
been observed and linked to HT.47   Furthermore, corticos-
teroids seem to induce HT by binding to mineralocorticoid 
receptors.49 It has been supported that although corticosteroids 
activate both mineralocorticoid and glucocorticoid receptors, 
they exhibit a higher affinity for glucocorticoid receptors than 
with mineralocorticoid receptors.50
On the other hand, corticosteroids negatively affect various 
vasodilatory systems.18,19 Corticosteroid-induced HT has been 
associated with nitric oxide (NO) deficiency through a range 
of negative influences on the NO biosynthetic pathways, 
involving i) alteration in the activity and expression of NO 
synthase, ii) decreased availability of tetrahydrobiopterin 
(BH4), and iii) decreased NO precursor l-arginine.51–53 NO 
deficiency might also be the result of NO interaction with 
excess superoxide to form a powerful oxidant, peroxynitrite, 
which leads to NO inactivation and deficit.54,55
According to experimental data, corticosteroids seem 
to negatively affect the production of other vasodilatory 
substances as well, such as prostacyclin, prostaglandin E2 
(PGE2), and kallikrein.56–58
The end result of the afore mentioned alterations is 
hemodynamic changes in various vascular beds. A large dose 
of oral DX (0.5 mg/kg/day) in dogs was accompanied by a 
reduction in cardiac output and an increase in   calculated total 
peripheral resistance.31 In humans, oral DX (1 mg three times 
daily for 7 days) increased mean and total peripheral vascular 
resistance without affecting the cardiac output.39 Limited stud-
ies support an effect of DX on the regional hemodynamics 
as well. Intravenous 24 h infusion of DX (125 mg/kg/h) 
increased the mean arterial pressure, and decreased renal and 
mesenteric blood flow and conductance.59 However, it remains 
unclear whether this is a coexisting feature or a pathogenic 
mechanism of corticosteroid-induced HT.
Coexisting metabolic abnormalities appear to   mediate 
and accentuate the corticosteroid-induced HT. Obesity 
is associated with a reduction in urine sodium excretion, 
increased plasma and extracellular fluid volume, and HT.18,19 
Insulin resistance leads to sodium and water retention, 
increased sympathoadrenal system activity, local renin–
angiotensin system  activation, vascular hypertrophy, increased 
vascular resistance, and HT.18,19 Sleep apnea has also been 
associated with HT through increased sympathetic tone 
during hypoxemic episodes, insulin resistance, and diabetic 
autonomic neuropathy.18,19Integrated Blood Pressure Control 2011:4 submit your manuscript | www.dovepress.com
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It seems that corticosteroids regulate blood pressure 
by exerting their effects at the central nervous system as 
well. Subcutaneous tritium-labeled DX administration in 
rats resulted in localization of radioisotope in the thalamus 
(lateral nucleus), hypothalamus (arcuate, ventromedial, 
periventricular, and paraventricular nuclei), and cell bodies 
of locus ceruleus, area postrema, and nucleus tractus solitarii, 
indicating that systemically administered DX passes to the 
brain and cerebrospinal fluid.60–62 An interesting theory 
has been developed suggesting that corticosteroids induce 
central nervous system activation and HT, but this has to be 
further evaluated.62 This effect might be mediated through 
direct interaction of corticosteroids with γ-aminobutyric acid 
type A and B receptors and nontranscriptional activation of 
phosphatidylinositol 3-kinase/protein kinase Akt pathway, 
possibly mediated by the glucocorticoid receptor.
Corticosteroid-induced CS  
and osteoporosis
Osteoporosis constitutes an important component of 
corticosteroid-induced CS in children and adults.1,2 Bone 
loss appears to be fastest in the first 6 months of therapy and 
persists at a slower rate thereafter, resulting in osteopenia 
and osteoporosis. Trabecular bone and the cortical rim 
of vertebral bodies appear to be more susceptible to the 
effects of corticosteroids, improving rapidly after their 
withdrawal. In addition, fractures may occur in 30%–50% of 
  corticosteroid-treated patients independently of bone mineral 
density differences.63,64 Long-term use of corticosteroids 
in asthmatic patients has been associated with increased 
rib and vertebral fractures.65 A retrospective cohort study 
of 244,235 adults on oral corticosteroids documented a 
dose-  dependent increase in nonvertebral, hip, forearm, and 
vertebral   fractures, occurring even with low doses of cor-
ticosteroids (2.5 mg/day).66 A meta-analysis of 42,500 men 
and women from seven prospective cohorts showed that 
current or prior corticosteroid use has been associated with 
increased fracture risk.67 There is a large body of evidence 
indicating that inhaled corticosteroids negatively affect 
bone metabolism, as well as when they are taken orally.68,69 
However, the percentage of bone loss and the real fracture 
risk attributed to corticosteroids is difficult to be estimated 
in those patients, due to the multifactorial origin of altered 
bone metabolism.
Corticosteroids negatively affect calcium metabolism and 
bone remodeling, leading to decreased bone formation and 
increased bone resorption. Corticosteroids decrease intes-
tinal calcium absorption and renal tubular reabsorption of 
calcium, resulting in hypercalciuria, secondary hyperparathy-
roidism, and increased bone resorption.63,64 Corticosteroids 
have a negative impact on osteoblastogenesis as well by 
reducing synthesis of type 1 collagen and insulin-like growth 
factor, altering the binding and thus the anabolic effects of 
transforming growth factor-β, inhibiting Wnt signaling, 
and inducing apoptosis of osteoblasts and osteocytes.63,64 
Decreased activity of type 1-11β-hydroxysteroid dehydro-
genase and increased activity of type 2-11β-hydroxysteroid 
dehydrogenase by circulating inflammatory cytokines, the 
antagonistic effect of corticosteroids on parathormone and 
testosterone, seem to represent underlying pathogenetic 
mechanisms. On the other hand, corticosteroids stimu-
late osteoclast proliferation by suppressing synthesis of 
osteoprotegerin, stimulating production of the receptor 
activator of nuclear factor κB and decreasing estrogen and 
androgen production, leading to increased osteoclastic bone 
resorption.63,64,70–72
Corticosteroid-induced CS and disorders 
of the coagulation/fibrinolysis system
Thromboembolic disease is an important and serious 
complication in patients with CS, as it is associated with 
increased morbidity and mortality.1,2,73 Small clinical studies in 
patients with CS have shown an activation of the coagulation 
system reflected in higher levels of plasma von Willebrand 
factor VIII, factor IX, and factor XII; decreased fibrinolytic 
activity reflected in lower levels of PAI-1, tPA, or euglobulin 
clot lysis time; and increased levels of factors XII, XI, IX, 
and VIII plasminogen and a 2-antiplasmin.74,75 These effects 
have been closely related to corticosteroids, as they were fully 
reversed after surgical treatment. In a similar way, exog-
enous corticosteroids cause disorders in the coagulation and 
  fibrinolytic systems, reflected in increased synthesis/secretion 
of PAI-1, and increased levels of thrombin–antithrombin 
complex increased plasma factor VII, factor VIII, factor XI, 
and fibrinogen levels.76–78
Corticosteroid-induced CS  
and muscloskeletal disorders
Myopathy seems to be a common feature in CS, clinically 
expressed as the inability to rise from a crouching position, 
due to the adverse effects of corticosteroids on the proximal 
muscles of the lower limb and the shoulder girdle.1,2,79 
Corticosteroids affect type 2B or ‘phasic’ muscle fibers 
(fast twitch) causing atrophy (but not necrosis), resulting in 
reduced muscle protein synthesis. This effect is mediated 
through increased oxidative phosphorylation, inhibition Integrated Blood Pressure Control 2011:4 submit your manuscript | www.dovepress.com
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of protein synthesis, and impairment of muscle membrane 
excitability.79
The acute form of myopathy involves proximal and   distal 
muscle weakness, is positively correlated with elevated serum 
creatinine phosphokinase levels, is an indicator of focal and 
diffuse muscle necrosis, is mediated by hypokalemia, or consti-
tutes the end result of a direct effect of corticosteroids on skel-
etal muscle. This type of myopathy may take between 6 weeks 
and several months to resolve, even after the   discontinuation of 
corticosteroids. The chronic form is more insidious in onset, 
primarily involves proximal muscle groups, and is character-
ized by typically normal or only slightly elevated creatinine 
phosphokinase levels with no evidence of focal or diffuse 
muscle necrosis. Although there is no direct correlation with 
dosage, patients who receive even small amounts of prednisone 
(ie, 10 mg/day) can develop myopathy.80,81
Corticosteroid-induced CS  
and metabolic syndrome
Impaired glucose tolerance, diabetes, dyslipidemia, and 
fatty liver disease are common findings in patients treated 
with corticosteroids.82–84 Not only experimental but also 
human data support the theory of corticosteroids having 
an effect on various sites involved in protein, lipid, and 
glucose metabolism, including skeletal muscle, liver, and 
adipose tissue. Corticosteroids induce insulin resistance 
in skeletal muscle by directly interfering with the insulin 
signaling cascade. Decreased glucogen synthesis rates and 
glycogen synthase concentration and activity have been 
found in skeletal muscle biopsies of healthy subjects on 
4 mg DX for 4 days85 and patients on long-term treatment 
with high doses of corticosteroids following renal trans-
plantation.86 Skeletal muscle insulin resistance is further 
aggravated by corticosteroid-induced protein catabolism 
with concomitant atrophy-related decrease in total muscle 
area and elevated circulating aminoacids,87 which negatively 
affect insulin signaling,88 glucose uptake, and glycogen 
synthesis in muscle.89 In addition, corticosteroids induce 
whole body lipolysis,89 resulting in increased plasma levels 
of free fatty acids and triglycerides90,91 with deleterious 
effects in skeletal muscle insulin sensitivity and glucose 
uptake. Corticosteroids induce hepatic insulin resistance 
as well, directly by interference with insulin signaling and 
indirectly by elevating free fatty acid and triglyceride supply 
to the liver.92 Thus, increased endogenous glucose production 
has been observed, especially in the postprandial state, as 
was demonstrated in healthy subjects following short-term 
exposure to corticosteroids.84,93,94 Corticosteroids increase 
body fat content and alter body fat distribution by regulating 
hormone sensitive lipase and lipoprotein lipase activity.95 In 
addition, corticosteroids modulate adipose tissue   biology 
by altering the secretion of adipokines either directly or 
through insulin resistance.96 In addition to inducing insulin 
resistance,   corticosteroids might exert an inhibitory effect 
on β cells, which is dependent on duration of exposure, 
dosage, and susceptibility of the population exposed. 
A prolonged exposure (2–5 days) of healthy subjects to high 
doses of corticosteroids resulted in fasting hyperinsulinemia 
and increased insulin secretion, possibly to compensate for 
the corticosteroid-induced insulin resistance.97–99 However, 
in a susceptible population, such as people with a reduced 
insulin sensitivity before treatment, people who are healthy 
first-degree relatives of patients with diabetes, and obese 
women, this compensation failed, resulting in β cell failure 
and diabetes.88,98–100 Thus, corticosteroids induce insulin 
resistance, impaired glucose metabolism, obesity, and central 
obesity, all of which are components of metabolic syndrome, 
which has been associated with increased morbidity and 
mortality from cardiovascular disease.
Corticosteroid-induced CS  
and cardiovascular disease
Patients with corticosteroid-induced CS exhibit increased 
cardiovascular morbidity and mortality.1,2,101–103 Increased 
mortality from cardiovascular disease has been reported 
in patients with asthma, chronic obstructive pulmonary 
disease, inflammatory arthritis, and giant cell arteritis.104–106 
A population-based study showed that patients who were 
exposed to systematic corticosteroids in a dose greater 
than the equivalent of 7.5 mg of prednisolone daily had 
substantially higher rates of cardiovascular disease dur-
ing 1–5 years of follow-up, namely myocardial infarction, 
heart failure, and cerebrovascular disease.102,103 It has to be 
mentioned that this association was not evident in patients 
treated with low doses or ‘nonsystemic’ (eg, topical and 
rectal) corticosteroids.
Corticosteroids appear to have a direct causal effect 
relationship with cardiovascular disease, which is dependent 
on the dose, duration, cumulative dose of exposure, and route 
of administration. Whether, and to what extent, the increased 
risk is mediated through the disease background for cardio-
vascular disease and the induction of several risk factors for 
cardiovascular disease and  represents a direct corticosteroid 
effect that is much higher than their anti-inflammatory and 
antiproliferative actions cannot be answered by the existing 
data.107,108Integrated Blood Pressure Control 2011:4 submit your manuscript | www.dovepress.com
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Corticosteroid-induced CS and fetal 
programming
Much interest has been focused over the last 5 years on 
the role of corticosteroids in fetal programming.1,2,109 The 
key mediators appear to be the hypothalamic–pituitary–
adrenal axis, the glucocorticoid receptor, and the expres-
sion of type 2-11β-hydroxysteroid dehydrogenase genes 
in a range of tissues. The administration of corticosteroids 
to mothers to promote maturation of organs in fetuses, to 
prevent a number of life-threatening complications of pre-
term birth, and to reduce the effects of congenital adrenal 
hyperplasia has undoubted short-term benefits and also 
potential   long-term adverse effects.109,110 A large body of 
experimental and human evidence supports the theory that 
corticosteroids appear to be involved in a dose-dependent 
manner in the fetal programming of adult diseases.111 
Corticosteroid-related fetal programming of adult HT is 
exerted through the effects on maturation of tissues involved 
in the control of blood pressure, such as glomerular number 
and kidney size, in the expression of catecholamine recep-
tors and second messenger systems in renal and vascular 
tissue, and by affecting growth factors and carbohydrate 
and fat homeostasis. In addition, corticosteroids potentiate 
vasoconstrictor effects on the   vasculature and regulate the 
synthesis of catecholamines, NO, and angiotensinogen.112,113 
HT is coupled to   tissue-specific increases in glucocorticoid 
receptor expression and downregulation of type 2-11β-
hydroxysteroid dehydrogenase activity in the placenta, 
kidney, and adrenal, increasing   sensitivity and overexposing 
organs to corticosteroids. Apart from inducing HT, corti-
costeroids are involved in the fetal programming of type 
2 diabetes, cardiovascular disease, other manifestations of 
the metabolic syndrome, several central nervous system 
functions, and psychiatric syndromes. However, the exact 
underlying pathogenetic mechanisms are still unclear and 
need to be further elucidated.
Exogenous vs endogenous 
corticosteroid-induced CS and HT
Although the clinical presentation of CS is quite similar 
from endogenous cortisol overproduction and exogenous 
corticosteroids, it also has some differences, mainly in 
the more striking clinical manifestations, due to the use 
of high doses of corticosteroids.1,2 CS as a result of the 
long-term usage of corticosteroids has less hirsutism and 
other virilizing features due to nonsignificant increases in 
androgens. In addition, HT is less profound in exogenous 
corticosteroid-induced CS compared with endogenous CS, 
depending on the form used. In contrast, avascular necrosis 
and spinal epidural lipomatosis occur primarily in the set-
ting of corticosteroid-induced CS.1,2 In addition, a kinetic 
difference has to be mentioned. In contrast to cortisol, 
most synthetic corticosteroids bind to albumin and not to 
cortisol-binding globulin or circulate as free steroids with 
a much higher affinity for the glucocorticoid receptor. With 
HT, both forms of CS exhibit some similarities and some 
differences.
In both forms of CS, the development of HT is rapid. 
Supraphysiological oral cortisol doses (80 and 200 mg/day) in 
humans can cause HT within 24 h, with peak blood pressure 
occurring at day 4 or 5 of treatment.114,115 In addition, subcu-
taneous DX (10 mg/day) in rats and oral DX (0.5 mg/kg/day) 
in dogs and humans (3 mg/day) increases blood pressure 
within 1–2 days.31 According to in vitro and in vivo studies, 
the same pattern is observed in endogenous CS as well.116,117 
HT, in both clinical entities, is independent of miner-
alocorticoid activity and sodium loading or retention.49,118 
However, in endogenous CS, sodium excess can magnify 
the   hypertensive response.119,120 Increased oxidative stress, 
reflected in increased superoxide production and elevated 
levels of plasma F2-isoprostanes, constitutes a common 
underlying disorder in both forms of CS and is prevented 
and reversed by antioxidants (folic acid, N-acetylcysteine, 
tempol, and apocynin) but not with BH4 or allopurinol.121–123 
In both conditions, HT has been associated with decreased 
NO bioavailability, reflected in decreased plasma reactive 
nitrogen intermediates (nitrate/nitrite).122,123
Although HT, in both forms of CS, is associated 
with increased oxidative stress and NO deficiency and 
inactivation, blood pressure response to treatments known 
to modify the synthesis of NO and superoxide seems to be 
  variable. l-Arginine treatment (500 mg/kg/day) increased 
plasma nitrate/nitrite concentrations but failed to prevent 
HT in corticosteroid-treated rats.53,121 In contrast, in endog-
enous CS, HT was prevented and partly reversed by l-argi-
nine treatment.124 Aspirin, an antioxidant and nonselective 
cyclooxygenase inhibitor, prevented and partly reversed HT 
related to endogenous but not exogenous CS.125 Vasopressin 
antagonism with an AVP-V1 receptor antagonist signifi-
cantly decreased mean arterial pressure in exogenous but 
not endogenous CS-related hypertensive rats.33 Both forms 
of HT exhibit a different response to glucocorticoid recep-
tor antagonism, suggesting a different degree of receptor 
activation in both situations. Thus, dehydroepiandroster-
one, an endogenous steroid with antiglucocorticoid activ-
ity, prevented corticosteroid-induced but not endogenous Integrated Blood Pressure Control 2011:4 submit your manuscript | www.dovepress.com
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cortisol-induced HT.31,126 In summary, it appears that HT 
due to endogenous or exogenous CS involves either differ-
ent pathophysiological mechanisms or different degree of 
perturbations of the same mechanisms.
Treatment
Patients with autoimmune or inflammatory disorders should 
be on long-term use of corticosteroids and may develop HT 
and other morbidities associated with corticosteroid-induced 
CS. The ideal treatment is the withdrawal of corticosteroids 
before the onset of comorbidities. However, this is practically 
impossible, as it is associated with exacerbation of the 
underlying disease. When possible, corticosteroids should be 
gradually withdrawn. The use of corticosteroids in low dos-
ages or on alternative days results in fewer metabolic effects 
and also helps in the prevention of corticosteroid-related 
pathology. Thus, each patient should be treated individually, 
following a careful, properly designed plan. In most cases, 
patients should be treated for corticosteroid-related morbidi-
ties. For HT, eplerenone, angiotensin receptor antagonists, 
and angiotensin-converting enzyme inhibitors are indicated. 
Weight loss is encouraged through changes in the life-
style. Medications that improve insulin resistance, such as 
biguanides and peroxisome proliferator-activated receptor 
agonists, should be added. Treatment of sleep apnea with 
a continuous positive airway pressure device appears to be 
generally effective in controlling not only apnea but also HT, 
insulin resistance, and increased risk for cardiovascular dis-
ease. Bisphosphonates are the first-line choice for prevention 
or treatment of osteoporosis, with teriparatide as the second-
line option; calcium and vitamin D supplements should be 
coprescribed in the majority of individuals. Muscle biopsy 
is recommended in patients who require long-term corti-
costeroid treatment and develop weakness during therapy. 
Phenytoin has been suggested for treatment of corticosteroid 
myopathy, but this still needs further research. In the absence 
of prospective randomized clinical trials, there is currently 
general agreement that patients with CS should be treated 
as having a prothrombotic disorder. However, future large 
prospective trials are needed to evaluate the type, intensity, 
and duration of thromboprophylaxis in patients with either 
endogenous CS or iatrogenic CS.
Conclusion
Corticosteroid-induced CS constitutes a major health prob-
lem with difficult handling. A careful plan for treatment, 
namely formulation, route, dose, and time of exposure, 
should be properly evaluated individually before patients start 
corticosteroids use. Corticosteroid-related complications 
should be treated properly, if evident, and prevention strategy 
involves changes in lifestyle and treatment with appropriate 
agents. The focus of the research should be on developing 
synthetic steroids with anti-inflammatory but fewer metabolic 
effects, which so far has been unsuccessful.
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